Solifenacin Succinate

A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

Also Known As:

2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-; Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate; Solifenacin; Vesicare; YM 905; YM905; 905, YM; Succinate, Solifenacin

Networked: 453 relevant articles (97 outcomes, 161 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Quinuclidines: 20
    - Solifenacin Succinate: 453
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - Tetrahydroisoquinolines: 44
        Solifenacin Succinate: 453

Experts

1.	Herschorn, Sender: 15 articles (09/2022 - 05/2010)
2.	Cardozo, Linda: 12 articles (03/2021 - 10/2004)
3.	Siddiqui, Emad: 11 articles (12/2019 - 08/2015)
4.	Robinson, Dudley: 10 articles (03/2021 - 10/2004)
5.	Forero-Schwanhaeuser, Sergio: 10 articles (01/2012 - 10/2008)
6.	Chapple, Christopher R: 9 articles (01/2019 - 01/2005)
7.	Huang, Moses: 9 articles (01/2019 - 09/2006)
8.	Drake, Marcus J: 9 articles (12/2017 - 12/2013)
9.	Kaplan, Steven A: 8 articles (01/2020 - 12/2009)
10.	Stoelzel, Matthias: 8 articles (12/2019 - 05/2017)

Related Diseases

1.	Overactive Urinary Bladder (Overactive Bladder) 01/01/2012 - "In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer)." 11/01/2004 - "In this study treatment with solifenacin 5 mg and 10 mg once daily significantly improved all the major symptoms of overactive bladder including frequency, urgency and incontinence. " 01/01/2023 - "Peroneal electrical transcutaneous neuromodulation is a safe and effective method for overactive bladder treatment associated with a significantly lower incidence of treatment-related adverse events compared to solifenacin and a considerably better benefit-risk profile." 10/01/2016 - "After solifenacin treatment, the overactive bladder symptom score and average voided volume were significantly improved and maintained for 3 years. " 01/01/2015 - "Application of solifenacin at a dose of 5 mg in patients with overactive bladder significantly reduces the severity of symptoms. "
2.	Nocturia 08/01/2006 - "Data from these trials show that solifenacin 5 and 10 mg once daily is significantly more effective than placebo at reducing urgency, incontinence, micturition frequency and nocturia and at increasing volume voided per micturition. " 12/01/2009 - "Solifenacin vs. placebo significantly improved daily episodes of urgency, incontinence and frequency but not nocturia. " 07/01/2007 - "Solifenacin significantly improved nocturia symptoms only in OAB patients without NP." 09/01/2005 - "Solifenacin significantly improved urgency, frequency, and nocturia symptoms and increased volume voided in OAB dry patients." 01/01/2020 - "Another patient complained of nocturia on postoperative day 14, which was relieved with solifenacin succinate. "
3.	Urinary Incontinence 05/01/2016 - "This study shows that solifenacin treatment is effective for treating urinary incontinence but may lead to changes in bowel patterns and affects overall quality of life (QoL). " 01/01/2019 - "Among the included studies only solifenacin succinate double-blind, randomized, placebo-controlled study was assessed as low risk of bias, and treatment led to an improvement in urinary incontinence. " 05/01/2015 - "In this pilot trial, solifenacin succinate treatment led to an improvement in urinary incontinence, despite persistence in other OAB symptoms." 06/01/2006 - "Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence." 10/01/2020 - "Moreover, two studies tested the effect of solifenacin on urinary incontinence. "
4.	Lower Urinary Tract Symptoms 09/01/2016 - "Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms." 01/01/2020 - "Effects of Tamsulosin Combined With Solifenacin on Lower Urinary Tract Symptoms: Evidence From a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials." 01/01/2016 - "Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study." 11/01/2013 - "Results of large, randomized trials of solifenacin in combination with tamsulosin in men with lower urinary tract symptoms, including voiding and storage ones, have dominated the medical literature on the subject for the past 12-16 months. " 09/01/2013 - "Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN)."
5.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/01/2017 - "Re: Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients with Benign Prostatic Hyperplasia." 03/01/2016 - "Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia." 01/01/2020 - "Re: The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia with Severe Lower Urinary Tract Dysfunction with Combination of Dutasteride and Solifenacin." 11/01/2018 - "The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin. " 11/01/2018 - "The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin."

Related Drugs and Biologics

1.	mirabegron
2.	Tolterodine Tartrate (Detrol)
3.	Tamsulosin (Flomax)
4.	Muscarinic Antagonists
5.	oxybutynin (Tavor)
6.	Tablets
7.	Cholinergic Antagonists (Anticholinergics)
8.	fesoterodine
9.	propiverine
10.	imidafenacin

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Aftercare (After-Treatment)
4.	Catheters
5.	Suburethral Slings (Tension-Free Vaginal Tape)